Various drugs are known to cause musculoskeletal symptoms, such as arthralgias, myalgias, drug-induced lupus and serum sickness.1 In the rheumatology world, the most commonly recognized drugs that can cause musculoskeletal symptoms are hydralazine, minocycline, fluoroquinolones and, recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor class of medications. Although beta blockers also have a noted side effect…
Sialendoscopy Enhances Salivary Flow in Sjogren’s Syndrome
NEW YORK (Reuters Health)—Sialendoscopy with irrigation of the major salivary glands can enhance salivary flow and reduce xerostomia in patients with Sjogren’s syndrome, according to a randomized trial. “In our study it is suggested that patients with recent onset of Sjogren’s syndrome and with residual salivary gland capacity could benefit from sialendoscopy,” said Dr. Derk…
ACR Members Begin Work on CMS Committees
TEP In February, Lisa Gale Suter, MD, joined the Technical Expert Panel (TEP) for the Centers for Medicare & Medicaid Services (CMS) Quality Measure Development Plan, supporting the transition to the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APMs). She was nominated to serve in this role by the ACR. The panel comprises…
Providers Using RISE Have Advantage with 2017 MIPS Reporting
Hundreds of rheumatology providers across the country are finalizing submissions for the first year of reporting under the Merit-Based Incentive Payment System (MIPS). According to a presentation at the 2017 ACR/ARHP Annual Meeting in San Diego, providers that participate in and submit through the Rheumatology Informatics System for Effectiveness (RISE) Registry are poised to perform…
Invest in RheumPAC Now to Support the Future of Rheumatology
If there’s one thing America needs right now, it’s more money in politics. I’m being facetious, but I do want to ask all of you to invest in RheumPAC today. Given the relatively small size of our subspecialty, it is easy for lawmakers to overlook the consequences that laws may have on our field of…
Connect Rheumatology: A Conversation with Paul Sufka, MD, ACR Committee on Marketing & Communications Member
The field of rheumatology is advancing fast—alongside communication technologies that generate a massive amount of information. Paul Sufka, MD, a rheumatologist with HealthPartners in St. Paul, Minn., is interested in the ways social media can help him and other rheumatologists stay connected and keep abreast of practice information. “One thing I see people doing too…
U.S. Health Spending Is Twice Other Countries’, with Worse Results
(Reuters Health)—The U.S. spends about twice what other high-income nations do on healthcare, but has the lowest life expectancy and the highest infant mortality rates, a new study suggests. More doctor visits and hospital stays aren’t the problem. Americans use roughly the same amount of health services as people in other affluent nations, the study…
Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis
In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…
Younger Patients Getting Knees & Hips Replaced
NEW YORK (Reuters Health)—Patients undergoing total joint replacement are younger now than they were in 2000, new research indicates. The average patient undergoing a total hip replacement (THR) in 2014 was 64.9 years, while the average patient in 2000 was 66.3 years. Similarly, the average patient undergoing a total knee replacement (TKR) was 65.9 in…
Study Finds Newer Gout Drug Poses Risk to Heart Patients
(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher…
- « Previous Page
- 1
- …
- 315
- 316
- 317
- 318
- 319
- …
- 778
- Next Page »